Literature DB >> 16505024

Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer.

John M Wild1, Catherine R Robson, Adrian L Jones, Ian A Cunliffe, Philip E M Smith.   

Abstract

PURPOSE: To quantify retinal nerve fiber layer thickness (RNFLT) and macular thickness (MT) in patients exhibiting vigabatrin-attributed visual field loss (VAVFL) and to determine the efficacy of these measures as markers of the retinal damage associated with vigabatrin.
METHODS: This was a prospective cross-sectional observational study involving five groups: Group I, 13 patients exhibiting VAVFL; Group II, 8 patients exposed to vigabatrin but with normal fields; Group III, 14 patients receiving carbamazepine monotherapy; Group IV, 20 normal individuals; and Group V, 7 patients receiving sodium valproate monotherapy. At one of two visits, the right eye of each participant underwent two digital imaging modalities: ocular coherence tomography (OCT; StratusOCT; Carl Zeiss Meditec, Dublin, CA) and scanning laser ophthalmoscopy (SLO; Heidelberg Retinal Tomograph; Heidelberg Engineering GmbH, Heidelberg, Germany). At the other visit, participants underwent three-zone, age-corrected suprathreshold perimetry of the whole field and threshold perimetry of the central field (Humphrey Field Analyzer 750; Carl Zeiss Meditec). The order of the visits was randomized.
RESULTS: The group mean RNFLT in Group I was attenuated relative to that of the remaining groups (all P < 0.001). At 100% specificity, based on the 95% confidence limits derived from Group IV, OCT exhibited 100% sensitivity and SLO 77% sensitivity for an attenuated RNFLT in patients with VAVFL. All participants manifested an MT within the normal range derived from Group IV.
CONCLUSIONS: OCT of the RNFL can efficiently identify vigabatrin-induced damage and will be useful for adults and children unable to perform perimetry and when the perimetric outcome is equivocal.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16505024     DOI: 10.1167/iovs.05-0854

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  16 in total

1.  Modelling the risk of visual field loss arising from long-term exposure to the antiepileptic drug vigabatrin: a cross-sectional approach.

Authors:  John M Wild; David L Fone; Saleh Aljarudi; Charlotte Lawthom; Philip E M Smith; Robert G Newcombe; Gareth D Lewis
Journal:  CNS Drugs       Date:  2013-10       Impact factor: 5.749

2.  Electroretinographic (ERG) responses in pediatric patients using vigabatrin.

Authors:  Anne Moskowitz; Ronald M Hansen; Susan E Eklund; Anne B Fulton
Journal:  Doc Ophthalmol       Date:  2012-03-20       Impact factor: 2.379

3.  Evaluation of inner retinal layers with optic coherence tomography in vigabatrin-exposed patients.

Authors:  Betül Tuğcu; Mesrure Köseoğlu Bitnel; Fatma Selin Kaya; Betül Tekin Güveli; Dilek Ataklı
Journal:  Neurol Sci       Date:  2017-05-16       Impact factor: 3.307

4.  Electroretinogram changes in a pediatric population with epilepsy: is vigabatrin acting alone?

Authors:  Bláthnaid McCoy; Thomas Wright; Shelly Weiss; Cristina Go; Carol A Westall
Journal:  J Child Neurol       Date:  2011-02-22       Impact factor: 1.987

5.  The Topographical Relationship between Visual Field Loss and Peripapillary Retinal Nerve Fibre Layer Thinning Arising from Long-Term Exposure to Vigabatrin.

Authors:  John M Wild; Saleh Aljarudi; Philip E M Smith; Carlo Knupp
Journal:  CNS Drugs       Date:  2019-02       Impact factor: 5.749

Review 6.  Applications of optical coherence tomography in pediatric clinical neuroscience.

Authors:  Robert A Avery; Raneem D Rajjoub; Carmelina Trimboli-Heidler; Amy T Waldman
Journal:  Neuropediatrics       Date:  2015-03-24       Impact factor: 1.947

7.  Reduced grating acuity associated with retinal toxicity in children with infantile spasms on vigabatrin therapy.

Authors:  Sivan Durbin; Giuseppe Mirabella; J Raymond Buncic; Carol A Westall
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-03-11       Impact factor: 4.799

8.  Visual field loss in patients with refractory partial epilepsy treated with vigabatrin: final results from an open-label, observational, multicentre study.

Authors:  John M Wild; Catherine Chiron; Hyosook Ahn; Michel Baulac; Joseph Bursztyn; Enrico Gandolfo; Ivan Goldberg; Francisco Javier Goñi; Florence Mercier; Jean-Philippe Nordmann; Avinoam B Safran; Ulrich Schiefer; Emilio Perucca
Journal:  CNS Drugs       Date:  2009-11       Impact factor: 5.749

9.  Treatment of epilepsy: the GABA-transaminase inhibitor, vigabatrin, induces neuronal plasticity in the mouse retina.

Authors:  Qing-Ping Wang; Firas Jammoul; Agnès Duboc; Jie Gong; Manuel Simonutti; Elisabeth Dubus; Cheryl M Craft; Wen Ye; José A Sahel; Serge Picaud
Journal:  Eur J Neurosci       Date:  2008-04       Impact factor: 3.386

10.  Full-field ERG and visual fields in patients 5 years after discontinuing vigabatrin therapy.

Authors:  Ulrika Kjellström; Monica Lövestam-Adrian; Sten Andréasson; Vesna Ponjavic
Journal:  Doc Ophthalmol       Date:  2008-01-10       Impact factor: 2.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.